The Role of Psychedelic-Assisted Therapies in Treating Depression
August 30, 2024 DOI: 10.64239/pi-vl8206 (opens in new tab)
Summary
AI-generated from the abstractPsychedelic-assisted therapy can reduce depression symptoms rapidly and durably for weeks to months in some trials. However, the largest trial to date reported a dose-dependent rise in suicidal ideation and behavior, indicating possible harms. Psychedelics also appear promising for treating depression and anxiety in people with terminal illnesses.
Study at a glance
| Characteristics | Review |
|---|---|
| Key finding | Psychedelic-assisted therapy shows rapid symptom reduction for depression but also a dose-dependent increase in suicidal ideation and behavior in the largest trial. |
Abstract
Psychedelic-assisted therapy trials for depression have shown robust, rapid symptom reduction lasting weeks to months after treatment in some studies. The largest trial to date found a dose-dependent increase in suicidal ideation and behavior, suggesting potential risks. Psychedelics show promise in addressing depression and anxiety related to terminal illnesses.